# Nocturnal BiPAP Therapy Improved Chronic Respiratory Failure in Chilaiditi Syndrome

**Authors:** Takeshi Kouga, Reizo Tsukamoto

PMC · DOI: 10.1002/jgf2.70102 · 2026-02-15

## TL;DR

A 79-year-old man with Chilaiditi syndrome experienced improved breathing and sleep after using BiPAP therapy at night.

## Contribution

This case report suggests that nocturnal BiPAP therapy can be an effective treatment for respiratory symptoms in Chilaiditi syndrome.

## Key findings

- The patient's dyspnea and sleep disturbance improved with nocturnal BiPAP therapy.
- BiPAP therapy may reduce diaphragmatic compression caused by intestinal enlargement.
- BiPAP should be considered as a treatment option for Chilaiditi syndrome patients.

## Abstract

Chilaiditi syndrome includes the Chilaiditi sign, a radiological finding where a segment of bowel loop or small intestine has wandered between the liver and diaphragm and also any symptoms related to intestinal interference.

We report the case of a 79‐year‐old man with Chilaiditi syndrome whose dyspnea and sleep disturbance improved after nocturnal biphasic positive airway pressure (BiPAP) therapy implementation.

BiPAP therapy may contribute to thoracic pressure elevation and reduce diaphragmatic compression due to intestinal enlargement, thus leading to improvements in respiratory symptoms.

BiPAP therapy should therefore be considered as a treatment option for Chilaiditi syndrome patients.

## Linked entities

- **Diseases:** Chilaiditi syndrome (MONDO:0043343)

## Full-text entities

- **Diseases:** Chilaiditi Syndrome (MESH:D059269), dyspnea (MESH:D004417), sleep disturbance (MESH:D012893), Chronic Respiratory Failure (MESH:D012131)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12907258/full.md

---
Source: https://tomesphere.com/paper/PMC12907258